“…However, Gd is limited in that it is invasive, expensive, and exhibits toxicity in certain patient populations (Kanda, et al ., 2015; Rogowska et al ., 2018; Schlaudecker and Bernheisel, 2009). On the other hand, generating dOHb contrast has thus far relied on gas control systems that modify dOHb concentration in the blood through the induction of hypoxia (Lee et al ., 2022; Poublanc et al ., 2021; Sayin et al ., 2022; Schulman et al ., 2023; Vu et al ., 2021), hyperoxia (MacDonald et al ., 2018), or hyper/hypocapnia (Vu et al ., 2023). Given the associated cost, set-up time, and expertise required for gas control system utilization, the widespread clinical implementation of dOHb contrast as an alternative to Gd is currently limited.…”